Market News
Global Small Volume Parenteral Market- Recent Developments
Product Approval and Launch
- On September 6, 2023, Amneal Pharmaceuticals, Inc., a pharmaceutical company, announced that they had received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is on the U.S. FDA shortage product list. Calcium gluconate in sodium chloride injection is a small volume parenteral bag indicated for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients.
- In May 2021, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company, launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (U.S.FDA).
Business Development Activities by the Market Players
- In November 2022, WuXi STA, a subsidiary of WuXi AppTec, a pharmaceutical company announced a new parenteral formulation manufacturing line which has started operation at the drug product site in Wuxi city, China. It is the second line opened for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 Mn units. This expansion demonstrates the company’s continuous commitment to enhance its injectable drug product platform.
- In March 2021, Syntegon Technology, a processing and packaging technology company, launched new small volume parenteral (SVP) essential, a cost-efficient version of its proven Pharmatec SVP process systems for the production of small-volume liquid pharmaceuticals.
U.S.: 
U.K. : 
India : 
